Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51,706 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.
Patel RB, Hernandez R, Carlson P, Grudzinski J, Bates AM, Jagodinsky JC, Erbe A, Marsh IR, Arthur I, Aluicio-Sarduy E, Sriramaneni RN, Jin WJ, Massey C, Rakhmilevich AL, Vail D, Engle JW, Le T, Kim K, Bednarz B, Sondel PM, Weichert J, Morris ZS. Patel RB, et al. Among authors: kim k. Sci Transl Med. 2021 Jul 14;13(602):eabb3631. doi: 10.1126/scitranslmed.abb3631. Sci Transl Med. 2021. PMID: 34261797 Free PMC article.
Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma.
Choi BS, Sondel PM, Hank JA, Schalch H, Gan J, King DM, Kendra K, Mahvi D, Lee LY, Kim K, Albertini MR. Choi BS, et al. Among authors: kim k. Cancer Immunol Immunother. 2006 Jul;55(7):761-74. doi: 10.1007/s00262-005-0069-7. Epub 2005 Sep 27. Cancer Immunol Immunother. 2006. PMID: 16187086 Free PMC article. Clinical Trial.
Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy.
Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, Maris JM, Sondel PM. Delgado DC, et al. Among authors: kim k. Cancer Res. 2010 Dec 1;70(23):9554-61. doi: 10.1158/0008-5472.CAN-10-2211. Epub 2010 Oct 8. Cancer Res. 2010. PMID: 20935224 Free PMC article. Clinical Trial.
Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.
Albertini MR, Hank JA, Gadbaw B, Kostlevy J, Haldeman J, Schalch H, Gan J, Kim K, Eickhoff J, Gillies SD, Sondel PM. Albertini MR, et al. Among authors: kim k. Cancer Immunol Immunother. 2012 Dec;61(12):2261-71. doi: 10.1007/s00262-012-1286-5. Epub 2012 Jun 8. Cancer Immunol Immunother. 2012. PMID: 22678096 Free PMC article. Clinical Trial.
Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.
Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM. Yang RK, et al. Among authors: kim k. J Immunol. 2012 Sep 1;189(5):2656-64. doi: 10.4049/jimmunol.1200934. Epub 2012 Jul 27. J Immunol. 2012. PMID: 22844125 Free PMC article.
51,706 results
You have reached the last available page of results. Please see the User Guide for more information.